Zenidolol

Synonyms: ICI-118551
Zenidolol (ICI-118551) 是一种选择性 β2 肾上腺素受体 (β2-adrenergic receptor) 拮抗剂,其对 β2、β1 和 β3 肾上腺素能受体的 Ki 值分别为 0.7、49.5 和 611 nM,通过阻断肿瘤细胞上的 β2-AR 诱导凋亡 (apoptosis)、抑制肿瘤球形成并下调 HIF 通路而发挥抗肿瘤作用,在小鼠模型中表现出独特的肺血管特异性舒张作用,并可作为降眼压剂用于眼科疾病研究。
产品编号: MS-R35803 纯度: 99.60% CAS No.: 72795-26-7 分子式: C17H27NO2 分子量: 277.40
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Zenidolol (ICI-118551) 是一种选择性 β2 肾上腺素受体 (β2-adrenergic receptor) 拮抗剂,其对 β2、β1 和 β3 肾上腺素能受体的 Ki 值分别为 0.7、49.5 和 611 nM,通过阻断肿瘤细胞上的 β2-AR 诱导凋亡 (apoptosis)、抑制肿瘤球形成并下调 HIF 通路而发挥抗肿瘤作用,在小鼠模型中表现出独特的肺血管特异性舒张作用,并可作为降眼压剂用于眼科疾病研究。

生物实验数据

生物活性 Zenidolol (ICI-118551) is a selective β2-adrenergic receptor antagonist with Ki values of 0.7, 49.5, and 611 nM for β2, β1, and β3 adrenergic receptors, respectively, and it exerts antitumor effects by blocking β2-AR on tumor cells to induce apoptosis, inhibit tumorsphere formation, and downregulate the HIF pathway, exhibits unique pulmonary vascular-specific vasodilation in mouse models, and can be used as an intraocular pressure-lowering agent in ophthalmic disease research.
体外研究
(In Vitro)

Zenidolol (0-200 μM; 48 h) 以剂量依赖方式降低 VHL 来源的血管母细胞瘤原代培养物的细胞活力,且相较于 HUVECs 对 HB 细胞具有更高的特异性。
Zenidolol (100 μM; 7 days) 可抑制 VHL 肿瘤来源的血管母细胞瘤原代培养物中血管球的形成。
Zenidolol (100 μM; 6 h) 可抑制人脐静脉内皮细胞 (HUVECs) 中的内皮细胞迁移和血管生成。
Zenidolol (100 μM; 48 h) 可削弱缺氧诱导的人脐静脉内皮细胞 (HUVECs) 和 VHL 来源的血管母细胞瘤原代培养物中 HIF-1α 的核转位。
Zenidolol (100 μM; 72 h) 可通过提高 caspase 3/7/9 活性,上调促凋亡基因 BAX 在 VHL 来源的血管母细胞瘤原代培养物中诱导细胞凋亡。
Zenidolol (100 μM; 48-72 h) 可抑制 VHL 来源的血管母细胞瘤原代培养物中 HIF 靶基因 AQP-1 的表达。
Zenidolol (10 μM) 可诱导牛肺动脉内皮细胞产生一氧化氮,使内皮型一氧化氮合酶的 Ser1177 位点发生磷酸化。

Cell Viability Assay

Cell Line: von Hippel-Lindau (VHL) disease-derived hemangioblastoma (HB) primary cultures, human umbilical vein endothelial cells (HUVECs)
Concentration: 0, 25, 50, 100 and 200 μM
Incubation Time: 48 h
Result: Decreased the viability of HB primary culture cells in a dose-dependent manner, with viability dropping to 40-45% at 100 μM compared to untreated cells. Maintained HUVEC viability at 80% at 100 μM compared to untreated cells.

Cell Migration Assay

Cell Line: human umbilical vein endothelial cells (HUVECs)
Concentration: 100 μM
Incubation Time: 6 h
Result: Delayed wound closure in HUVECs, significantly impairing endothelial cell migration compared to untreated controls.

Immunofluorescence

Cell Line: hypoxia-induced human umbilical vein endothelial cells (HUVECs), von Hippel-Lindau (VHL) disease-derived hemangioblastoma (HB) primary cultures
Concentration: 100 μM
Incubation Time: 48 h
Result: Shifted HIF-1α localization from predominantly nuclear to a mix of cytoplasmic and nuclear in DFO-treated HUVECs compared to controls.
Reduced nuclear HIF-1α localization in HB cells compared to untreated controls, where HIF-1α was mainly nuclear.

Apoptosis Analysis

Cell Line: von Hippel-Lindau (VHL) disease-derived hemangioblastoma (HB) primary cultures
Concentration: 100 μM
Incubation Time: 72 h
Result: Induced a 1.7-fold increase in caspase 3/7 activity in HB cells compared to untreated controls. Significantly upregulated mRNA expression of BAX (1.3-2 fold) and Caspase 9 (1.3-2 fold) compared to untreated controls.

Real Time qPCR

Cell Line: von Hippel-Lindau (VHL) disease-derived hemangioblastoma (HB) primary cultures (HB19, HB23, HB28)
Concentration: 100 μM
Incubation Time: 48 and 72 h
Result: Significantly decreased mRNA expression of AQP-1 (a HIF-1α target gene) in multiple HB primary cultures compared to untreated controls.

Western Blot Analysis

Cell Line: bovine pulmonary arterial endothelial cells (bPAECs)
Concentration: 10 μM
Incubation Time: 2, 5, 10 minutes
Result: Induced time-dependent phosphorylation of eNOS at Ser1177, with normalized p-eNOS/β-actin values increasing over the 10-minute incubation period.
体内研究
(In Vivo)

Zenidolol (5-500 μg/kg; i.v.; 累计给药) 是一种强效的 β2-选择性肾上腺素能受体拮抗剂,在麻醉 Beagle 犬中,其对血管 β2-受体的亲和力比对心脏 β1-受体的亲和力至少高 250 倍。
Zenidolol (50-1000 μg/kg; i.v.; 累计给药) 可阻断血管 β2-受体的剂量不会影响麻醉 Beagle 犬对交感神经刺激的心脏反应,但高剂量 (1 mg/kg) 可抑制 SNS 诱导的心率升高。
Zenidolol (0.25-2.0%, 30 μg/kg; 局部眼部用药, 皮下给药; 单次给药) 是一种具有极低心脏副作用的强效眼降压剂,对阻断心脏 β-肾上腺素受体介导的反应弱。
Zenidolol (0.2 mg/kg; 颈静脉注射; 单次给药) 能显著降低小鼠肺动脉收缩压,但对体动脉收缩压无影响。

Animal Model: Beagle dogs (either sex, weight 10-15 kg, anaesthetised with pentobarbitone sodium)
Dosage: 5, 10, 20, 40, 100, 200, 500 μg/kg
Administration: i.v.; cumulative; each dose given 10 minutes before isoproterenol dose-response curve construction
Result: Caused a dose-dependent parallel shift to the right of the isoproterenol vasodilator curve; did not significantly alter isoproterenol chronotropic response curves even at the highest dose of 500 μg/kg (0.5 mg/kg); showed an effective dissociation constant (Kᵦ') of 2.1 μg/kg at vascular β₂-receptors; exhibited at least a 250-fold greater affinity for vascular β₂-receptors than cardiac β₁-receptors.
Animal Model: Beagle dogs (either sex, weight 10-18 kg, anaesthetised with pentobarbitone sodium)
Dosage: 50, 200, 1000 μg/kg (1 mg/kg)
Administration: i.v.; cumulative
Result: Caused a 10-30-fold shift to the right of the isoproterenol vasodilator dose-response curve at 50, 200 μg/kg without significantly reducing heart rate increases due to sympathetic nerve stimulation (SNS); induced significant antagonism of the SNS chronotropic response at the highest dose of 1000 μg/kg (1 mg/kg).
Animal Model: Beagle dogs (either sex, weight 10-17 kg, anaesthetised with pentobarbitone sodium)
Dosage: 10, 20, 40, 100, 200, 1000 μg/kg
Administration: i.v.; cumulative
Result: Produced no significant changes in resting heart rate, LV dP/dtₘₐₓ, diastolic blood pressure, or AVCT over the dose range 10-1000 μg/kg; caused a trend toward reduced aortic flow, likely due to prolonged anaesthesia rather than the reagent itself.
Animal Model: New Zealand white (male, 2-4 kg)
Dosage: 0.25%, 0.5%, 1.0%, 2.0% (topical ocular IOP studies); 30 μg/kg (subcutaneous IOP studies); 1% (topical ocular cardiac response study)
Administration: topical ocular, 50 μl or two 25 μl doses 5 min apart; s.c., single dose
Result: Caused a dose-dependent IOP decrease (maximal 4.2 mmHg at 1% at 1 hour post-administration; significant decreases at 0.25%, 0.5%, 1.0%, 2.0%).
Showed a greater and more prolonged IOP decrease in time-course studies, with maximal effect at 1-3 hours and persistence beyond 4 hours.
Induced a rapid IOP decrease (maximal at 1 hour, returning to normal by 6 hours) after subcutaneous 30 μg/kg administration.
Exhibited an IC50 of 176 μg/kg for blocking isoprenaline-induced cardio-acceleration when given systemically. Produced no effect on cardiac response to isoprenaline when given topically.
Animal Model: KO mice (C57/Bl6)
Dosage: 0.2 mg/kg
Administration: Intravenous injection via jugular vein; single administration
Result: Significantly reduced pulmonary artery systolic pressure (by approximately 25%), but has no effect on systemic artery systolic pressure.
性状 固体
颜色 White to off-white

化学信息

分子量 277.40
分子式 C17H27NO2
CAS No. 72795-26-7
别名 ICI-118551

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (360.49 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.6049 mL18.0245 mL36.0490 mL90.1226 mL
5 mM0.7210 mL3.6049 mL7.2098 mL18.0245 mL
10 mM0.3605 mL1.8025 mL3.6049 mL9.0123 mL
15 mM0.2403 mL1.2016 mL2.4033 mL6.0082 mL
20 mM0.1802 mL0.9012 mL1.8025 mL4.5061 mL
25 mM0.1442 mL0.7210 mL1.4420 mL3.6049 mL
30 mM0.1202 mL0.6008 mL1.2016 mL3.0041 mL
40 mM0.0901 mL0.4506 mL0.9012 mL2.2531 mL
50 mM0.0721 mL0.3605 mL0.7210 mL1.8025 mL
60 mM0.0601 mL0.3004 mL0.6008 mL1.5020 mL
80 mM0.0451 mL0.2253 mL0.4506 mL1.1265 mL
100 mM0.0360 mL0.1802 mL0.3605 mL0.9012 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础